MRNA vs PLX · rev $145.0M vs P/E 31, rev $53.6M
Moderna Inc (MRNA) versus Protalix Biotherapeutics Inc (PLX) — a side-by-side from cached financials, not a winner call.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
Latest reported PLX revenue for 2026-06-30 was $53.6M. Net income was $22.1M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
MRNA currently screens at market cap $24.52B. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Not investment advice. Open the MRNA and PLX stock pages for the full models.
Not investment advice.